烏龍製藥 URGN 深 滬
等待開盤 06-19 09:30:00 美东时间
32.83
+0.020
+0.06%
華盛通- 最 高33.79
- 今 開33.45
- 成交量 48.30万股
- 最 低 32.21
- 昨 收 32.81
- 總市值 16.00亿
- 52周最高 33.79
- 市盈率 靜 --
- 換手率 0.99%
- 52周最低 12.73
- 委 比 -98.30%
- 總股本 4872.17万
- 歷史最高 69.568
- 量 比 1.09
- 振 幅 4.82%
- 歷史最低 3.42
- 每 手 1
- 風險率 4.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alvotech gains on FDA acceptance of Entyvio biosimilar BLA
Alvotech (ALVO) shares rose in premarket trading on Monday after the company said the U.S. Food and Drug Administration accepted for review its Biologics License Application for AVT16, a proposed inte...
06-08 16:29
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. announced the grant of inducement restricted stock units (RSUs) to 21 new employees, totaling up to 102,700 ordinary shares. The RSUs vest equally over three years and support the commercialization of JELMYTO® and ZUSDURI™, as well as the company's pipeline development. UroGen is a biotech company focused on innovative treatments for urothelial and specialty cancers using its proprietary RTGel® technology.
06-05 12:00
UroGen Pharma Announces Settlement And License Agreement With Teva Pharmaceuticals Relating to JELMYTO
This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration ("FDA") seeking approval to market a
06-02 20:02
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
UroGen Pharma Ltd. announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8-10, 2026, in Miami Beach, FL. The event will include a fireside chat and 1x1 investor meetings on June 10, 2026, at 8:40 AM ET. A webcast will be available on UroGen’s corporate website under "Events & Presentations," with a replay accessible for 90 days. UroGen, a biotech company focused on urothelial and specialt...
06-01 20:10
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer
The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION trial. ZUSDURI is
05-15 20:06
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma's UGN-103 achieved a 94.5% durability of response at six months in the Phase 3 UTOPIA trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), aligning with ZUSDURI's 91.9% result in the ENVISION trial. UroGen plans to submit an NDA for UGN-103 in Q3 2026, leveraging its streamlined manufacturing and RTGel technology, with patent protection until 2041.
05-15 12:00
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $34 to $40.
05-07 20:57
